Tmunity Therapeutics, founded in 2015, is at the forefront of biotech innovation, striving to reshape the landscape of immunotherapy through its pioneering work in T cell engineering. The company emphasizes T Cell Receptor (TCR) engineered T cells, regulatory T cells (Treg), and universal engineered T cell platforms, aimed at exerting precise control over T cell behavior.
Strategically, Tmunity has proprietary technologies that enhance the activation, expansion, and genetic programming of T cells derived from peripheral and cord blood, as well as tumors. It is advancing towards clinical trials for next-gen immunotherapies to tackle oncology, infectious diseases, and autoimmune disorders.
Significantly, the company's founding team is distinguished by expertise in T-cell biology and cell therapy trial execution, which ensures the enhancement of safety and efficacy. Tmunity most recently attracted an acquisition investment from Kite Pharma on 01 December 2022, underscoring robust investor confidence and sectoral relevance.
American Gene Technologies® International Inc.
ImaginAb
Celularity Inc.
